

SCIENTIFIC PROGRAM (as of June 10, 2015)

Tuesday, June 16, 2015

- 09:30 – 17:30
Auditorium,
University
Campus
- CLOSED WORKSHOP: “FOLLICULAR LYMPHOMA: RECENT INSIGHTS AND FUTURE DIRECTIONS (MOVING TOWARDS BIOLOGY-DRIVEN TREATMENTS?)”***
Co-Chairs: R.D. Gascoyne, Vancouver, BC (Canada) and E. Zucca, Bellinzona (Switzerland)
Supported by American Association for Cancer Research - AACR and European School of Oncology – ESO
***by invitation only**
- 12:00 – 14:00
satellite
symposium
Room B I
- AMGEN (EUROPE) GmbH
NOVEL APPROACHES TO LYMPHOMA AND LEUKAEMIA: ENGAGING THE T CELL WITH BISPECIFIC ANTIBODY CONSTRUCTS
Chair: M. Ghilmini, Bellinzona (Switzerland)
- 15:00 – 18:00
Cinema
Corso
- WORKSHOP ON RADIOTHERAPY FOR LYMPHOMA: “CONTROVERSIES IN THE USE OF RADIATION THERAPY FOR ADVANCED STAGE LYMPHOMA”****
Co-Chairs: D. Hodgson, Toronto, ON (Canada) and T. Illidge, Manchester (UK)
Organized by International Lymphoma Radiation Oncology Group - ILROG
****open to all 13-ICML attendees**
- 15:00
- RADIATION THERAPY FOR ADVANCED STAGE HL
D. Hodgson, Toronto, ON (Canada)
- 15:30
- RADIATION THERAPY FOR ADVANCED STAGE DLBCL
G. Mikhaeel, London (UK)
- 16:00
- RADIOTHERAPY FOR RELAPSED AND REFRACTORY LYMPHOMA
J. Yahalom, New York, NY (USA)
- 16:30
- IMPLEMENTATION OF ADVANCED RADIOTHERAPY TECHNOLOGY: PLANNING AND TREATMENT
B.S. Dabaja, Houston, TX (USA)
- 17:00
- INCORPORATION OF FUNCTIONAL IMAGING INTO RT DELIVERY FOR LYMPHOMA
L. Specht, Copenhagen (Denmark)
- 17:30
- NEW AGENTS FOR ADVANCED STAGE LYMPHOMA – IMPLICATIONS FOR RADIATION ONCOLOGY
T.M. Illidge, Manchester (UK)
- 15:30 – 17:30
2 parallel
satellite
symposia
Room B I
- NOVARTIS ONCOLOGY
MORE EVIDENCE, MORE OPTIONS: FIRST-LINE TREATMENT OF CLL
Chair: K. Stamatopoulos, Thessaloniki (Greece)
- Room B II
- CTI LIFE SCIENCES LIMITED AND SERVIER
CHANGING EXPECTATIONS IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE NHL
Chair: M. Ghilmini, Bellinzona (Switzerland)

19:00 – 21:00
3 parallel
satellite
symposia
Room A

BRISTOL-MYERS SQUIBB
**IMMUNO-ONCOLOGY: A NEW ERA IN HEMATOLOGY TREATMENT?
EMERGING RESEARCH IN LYMPHOMA AND MYELOMA**
Chair: A. Engert, Cologne (Germany)

Room B I

BAYER HEALTHCARE PHARMACEUTICALS, INC.
**THE EVOLVING THERAPEUTIC POTENTIAL OF PI3K INHIBITORS IN RELAPSED NON-
HODGKIN'S LYMPHOMA**
Chair: M. Ghelmini, Bellinzona (Switzerland)

Room B II

TAKEDA ONCOLOGY, SEATTLE GENETICS, INC, THE LEUKEMIA LYMPHOMA SOCIETY
AND MEDICOM WORLDWIDE, INC.
CONTEMPORARY THERAPY FOR HODGKIN LYMPHOMA: WHERE ARE WE NOW?
Chair: F. Cavalli, Bellinzona (Switzerland)

Wednesday, June 17, 2015

08:30 – 12:00
Marquee

POSTER SESSION SET UP

08:30 – 09:15
5 parallel
sessions

Article
number

"MEET THE PROFESSOR" SESSIONS

Room A

IV.

MASSES IN THE MEDIASTINUM: PRIMARY MEDIASTINAL LYMPHOMA AND
INTERMEDIATE TYPES
P.M.W. Johnson, Southampton (UK)
repeated on Thursday, June 18, in Auditorium, University Campus

Room B

VII.

ARE LYMPHOMAS DRIVEN BY EPIGENETIC LESIONS?
A.M. Melnick, New York, NY (USA)
repeated at 09:30 in Cinema Corso

Cinema Corso

X.

CHALLENGES AND FUTURE DIRECTIONS IN PERIPHERAL T-CELL LYMPHOMA
K.J. Savage, Vancouver, BC (Canada)
repeated at 09:30 in Room B

Auditorium,
University
Campus

III.

CURRENT CONCEPTS IN PRIMARY CENTRAL NERVOUS LYMPHOMA
G. Illerhaus, Stuttgart (Germany)
repeated on Thursday, June 18, in Cinema Corso

Aula Magna,
University
Campus

IX.

IS IT ONLY ABOUT MYC? HOW TO APPROACH THE DIAGNOSIS OF DIFFUSE
LARGE B-CELL LYMPHOMAS
L. Quintanilla-Martinez, Tuebingen (Germany)
repeated on Friday, June 19, in Cinema Corso

09:30 – 10:15
5 parallel
sessions
Room A

VIII.

TREATMENT OF CLL, WHERE ARE WE HEADING?
S.M. O'Brien, Irvine, CA (USA)
repeated on Friday, June 19, in Auditorium, University Campus

Room B

X.

CHALLENGES AND FUTURE DIRECTIONS IN PERIPHERAL T-CELL LYMPHOMA
K.J. Savage, Vancouver, BC (Canada)

Cinema Corso	VII.	ARE LYMPHOMAS DRIVEN BY EPIGENETIC LESIONS? A.M. Melnick, New York, NY (USA)
Auditorium, University Campus	XII.	THERAPEUTIC EXPLOITATION OF AUTOLOGOUS T-CELL ACTIVATION IN B-CELL LYMPHOMA A. Younes, New York, NY (USA) <i>repeated on Thursday, June 18, in Room A</i>
Aula Magna, University Campus	VI.	FDG-PET AS A BIOMARKER IN LYMPHOMA: FROM QUALITATIVE TO QUANTITATIVE ANALYSIS M. Meignan, Creteil (France) <i>repeated on Friday, June 19, in Aula Magna, University Campus</i>
10:15 – 10:35 Marquee		COFFEE BREAK
10:35 – 12:00 <i>2 parallel sessions</i> Room A and Marquee (overflow area)		EDUCATIONAL SYMPOSIA 🎤
		HISTOLOGICAL TRANSFORMATION IN LYMPHOMA: CLINICAL, PATHOLOGICAL AND MOLECULAR FEATURES Chair: J.G. Gribben, London (UK)
		LECTURES:
	XIII.	MOLECULAR PATHOGENESIS OF TRANSFORMED LYMPHOMAS D. Rossi, Novara (Italy)
	XIV.	THE PATHOLOGY OF TRANSFORMATION OF LYMPHOMA R.D. Gascoyne, Vancouver, BC (Canada)
	XV.	CLINICAL ASPECTS OF TRANSFORMED LYMPHOMA J.G. Gribben, London (UK)
Room B		HODGKIN LYMPHOMA – CHALLENGES AND OPPORTUNITIES Chair: R.H. Advani, Stanford, CA (USA)
		LECTURES:
	XVI.	EARLY STAGE HODGKIN LYMPHOMA J.A. Radford, Manchester (UK)
	XVII.	TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA A. Engert, Cologne (Germany)
	XVIII.	MANAGEMENT OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA R.H. Advani, Stanford, CA (USA)
12:00 – 18:30 Marquee	Abstract number	POSTER SESSION (printing of the posters sponsored by Takeda Oncology)
	148 - 170	PATHOLOGY AND BIOLOGY
	171 - 181	HODGKIN LYMPHOMA
	182 - 186	CLL
	187 - 201	INDOLENT LYMPHOMA
	202 - 209	MANTLE CELL LYMPHOMA
	210 - 224	AGGRESSIVE B-CELL LYMPHOMA
	225 - 230	EXTRANODAL LYMPHOMA
	231 - 250	T-CELL LYMPHOMA
	251 - 259	IMAGING
	260 - 279	PRE-CLINICAL STUDIES
	280 - 287	EARLY CLINICAL TRIALS
	OT07 –	ONGOING TRIALS
	OT15	

12:00 – 13:00
Marquee

LUNCH TIME AND POSTER VIEWING

13:00 – 14:00
Room A, B and
Marquee
(overflow area)

OPENING OF THE CONFERENCE 🎤
WELCOME AND INTRODUCTORY REMARKS
F. Cavalli, Bellinzona (Switzerland)

**HENRY KAPLAN MEMORIAL LECTURE AND SAN SALVATORE FOUNDATION
AWARD** 🎤

Introduction to San Salvatore Foundation: L. Butti, Lugano (Switzerland)

Laudatio: R. Stahel, Zurich (Switzerland)

001 THERAPY OF LYMPHOMA INSPIRED BY FUNCTIONAL AND STRUCTURAL
GENOMICS
L.M. Staudt, Bethesda, MD (USA)

14:00 – 15:15
Room A, B and
Marquee
(overflow area)

PLENARY SESSION
Co-Chairs: G.P. Canellos, Boston, MA (USA) and J.W. Friedberg, Rochester, NY (USA)

14:00 008 RESPONSE-ADAPTED THERAPY BASED ON INTERIM FDG-PET SCANS IN
ADVANCED HODGKIN LYMPHOMA: FIRST ANALYSIS OF THE SAFETY OF DE-
ESCALATION AND EFFICACY OF ESCALATION IN THE INTERNATIONAL RATHL
STUDY (CRUK/07/033)
P.M.W. Johnson, Southampton (UK)

14:15 Discussant: A. Engert, Cologne (Germany)

14:25 009 ADDITION OF THIOTEPA AND RITUXIMAB TO ANTIMETABOLITES SIGNIFICANTLY
IMPROVES OUTCOME IN PRIMARY CNS LYMPHOMA: FIRST RANDOMIZATION OF
THE IELSG32 TRIAL
A.J. Ferreri, Milan (Italy)

14:40 Discussant: T.T. Batchelor, Boston, MA (USA)

14:50 010 NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOID
MALIGNANCIES AND CLASSICAL HODGKIN LYMPHOMA: UPDATED RESULTS OF
A PHASE 1 STUDY (CA209-039)
J. Timmerman, Los Angeles, CA (USA)

15:05 Discussant: A. Younes, New York, NY (USA)

15:15 – 15:40
Marquee

COFFEE BREAK

15:40 – 16:40
Room A, B and
Marquee
(overflow area)

AACR-ICML JOINT SESSION: SPECIAL LECTURES
Co-Chairs: F. Cavalli, Bellinzona (Switzerland) and M. Foti, Philadelphia, PA (USA)

15:40 004 UPDATE ON THE REVISION OF THE WHO LYMPHOMA CLASSIFICATION
S.H. Swerdlow, Pittsburgh, PA (USA)

16:10 005 WHAT'S NEW IN MULTIPLE MYELOMA?
S.V. Rajkumar, Rochester, MN (USA)

16:40 – 17:15

BREAK

17:15 – 18:15

6 parallel
sessions
Room A

“FOCUS ON...” SESSIONS

IMiDs IN LYMPHOMA

Chair: N. Fowler, Houston, TX (USA)

- 17:15 011 INDEPENDENT REVIEW OF CT RESPONSES IN THE TRIAL SAKK35/10
COMPARING RITUXIMAB WITH OR WITHOUT LENALIDOMIDE IN UNTREATED FL
PATIENTS IN NEED OF THERAPY
E. Zucca, Bellinzona (Switzerland)
- 17:25 012 RITUXIMAB+LENALIDOMIDE IN MALT LYMPHOMA: FINAL RESULTS
M. Raderer, Vienna (Austria)
- 17:35 013 LENALIDOMIDE ADDED TO BENDAMUSTINE-RITUXIMAB FOR UNTREATED
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PHASE 1 STUDY
J.S. Abramson, Boston, MA (USA)
- 17:45 014 RITUXIMAB, LENALIDOMIDE, BENDAMUSTINE SECOND LINE THERAPY IN
MANTLE CELL LYMPHOMA: A PHASE II STUDY OF THE FONDAZIONE ITALIANA
LINFOMI (FIL)
F. Zaja, Udine (Italy)
- 17:55 015 RITUXIMAB, BENDAMUSTINE AND LENALIDOMIDE IN PATIENTS WITH
RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMA NOT ELIGIBLE FOR
SALVAGE CHEMOTHERAPY. PHASE II TRIAL - SAKK 38/08
F. Hitz, St. Gallen (Switzerland)
- 18:05 016 A PHASE I/II TRIAL OF THE COMBINATION OF ROMIDEPSIN AND LENALIDOMIDE
IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA AND MYELOMA
N. Mehta-Shah, New York, NY (USA)

Room B

GENOMIC ALTERATIONS

Chair: G. Gaidano, Novara (Italy)

- 17:15 017 SEQUENCE-BASED PANOMICS ANALYSES BY THE ICGC MMML-SEQ DECIPHERS
MULTI-LAYER PATHWAY DEREGLATION IN GERMINAL CENTER DERIVED B-
CELL LYMPHOMAS
R. Siebert, Kiel (Germany)
- 17:25 018 STRUCTURAL VARIANTS IN GERMINAL-CENTER DERIVED B-CELL LYMPHOMAS:
ANALYSES IN THE FRAMEWORK OF THE ICGC MMML-SEQ PROJECT
C. Lopez, Kiel (Germany)
- 17:35 019 COMPREHENSIVE GENOMIC PROFILING OF DIFFUSE LARGE B-CELL LYMPHOMA
IN THE CLINICAL SETTING
J. He, Cambridge, MA (USA)
- 17:45 020 TARGETED GENOMIC SEQUENCING PROSPECTIVELY IDENTIFIES CLINICALLY
RELEVANT GENETIC ALTERATIONS ACROSS LYMPHOMA SUBTYPES
C.L. Batlevi, New York, NY (USA)
- 17:55 021 POSTTRANSPLANT DIFFUSE LARGE B-CELL LYMPHOMA AND BURKITT
LYMPHOMA: NEW GENETIC FINDINGS
I. Wlodarska, Leuven (Belgium)

18:05 022 MICRORNA-150 INFLUENCES MICROENVIRONMENTAL INTERACTIONS AND PROGNOSIS OF FOLLICULAR LYMPHOMA
M. Mraz, Brno (Czech Republic)

Room C

CLINICOPATHOLOGICAL CORRELATIONS

Chair: M.A. Piris, Santander (Spain)

17:15 023 FREQUENCIES OF LYMPHOMA ENTITIES AND IMPACT OF DIAGNOSTIC REVIEW: A FRENCH EXPERIENCE ON 35.753 LYMPHOMAS OVER 2010-2013
C. Laurent, Toulouse (France)

17:25 024 RITUXIMAB TREATMENT IN FOLLICULAR LYMPHOMA CIRCUMVENTS THE PROGNOSTIC VALUE OF INTRA-TUMORAL T-CELLS: AUTOMATED IMAGE ANALYSIS OF THE LYSA PRIMA TRIAL
L. Xerri, Marseille (France)

17:35 025 CELL OF ORIGIN (COO) ASSIGNMENT IN TRANSFORMED FOLLICULAR LYMPHOMA
R. Kridel, Vancouver BC (Canada)

17:45 026 NOTCH1/2 MUTATIONS ARE RECURRENTLY FOUND IN CYCLIN D1-NEGATIVE SOX11-POSITIVE MANTLE CELL LYMPHOMA
I. Salaverria, Barcelona (Spain)

17:55 027 CLINICOPATHOLOGICAL STUDY OF HHV8-NEGATIVE BODY CAVITY-BASED LYMPHOMA (BCBL)
D. Kaji, Tokyo (Japan)

18:05 028 GREY ZONE LYMPHOMA BETWEEN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B CELL LYMPHOMA: A LYSA RETROSPECTIVE ANALYSIS
C. Sarkozy, Pierre Bénite (France)

Cinema Corso

TRANSPLANTATION

Chair: S. Montoto, London (UK)

17:15 029 BEAM PLUS RITUXIMAB OR RADIOIMMUNOTHERAPY VERSUS BEAM FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED FOLLICULAR LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWP-EBMT
L. Bento, Paris (France)

17:25 030 OUTCOME OF REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER A PREVIOUS AUTOLOGOUS STEM CELL TRANSPLANT
S. Robinson, Bristol (UK)

17:35 031 A UK LYMPHOMA CLINICAL STUDY GROUP PHASE II EVALUATION OF HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN INTESTINAL AND OTHER AGGRESSIVE T-CELL LYMPHOMAS
M.M. Lannon, Newcastle upon Tyne (UK)

17:45 032 ALLOGENEIC TRANSPLANTATION FOR T-CELL LYMPHOMAS: NO DIFFERENCE IN OUTCOME BETWEEN PATIENTS ALLOGRAFTED UP-FRONT AND IN FIRST CHEMOSENSITIVE RELAPSE
A. Doderio, Milan (Italy)

17:55 033 ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION AS FIRST-LINE THERAPY FOR YOUNGER PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA - RESULTS OF THE INTERIM ANALYSIS OF THE AATT TRIAL
N. Schmitz, Hamburg (Germany)

18:05 034 POST TRANSPLANT CYCLOPHOSPHAMIDE REDUCES NON RELAPSE MORTALITY OF HAPLO-IDENTICAL TRANSPLANTS YIELDING SIMILAR OUTCOMES AS WITH MATCHED SIBLING DONORS
S. Dietrich, Heidelberg (Germany)

Auditorium,
University
Campus

NOVEL AGENTS

Chair: G. Salles, Pierre Bénite (France)

17:15 035 LIPID ADDICTION OF DLBCL: INVOLVEMENT OF PI3K SIGNALING AND POTENTIAL THERAPEUTIC STRATEGIES VIA FATTY ACID SYNTHASE SMALL MOLECULE INHIBITORS
A. Evens, Boston, MA (USA)

17:25 036 EZH2 AND MYD88 MUTATIONS APPEAR ASSOCIATED WITH ANTITUMOR ACTIVITY OF THREE NEW BET BROMODOMAIN INHIBITORS (BAY-5627, BAY-7575 AND BAY-8097) IN PRECLINICAL LYMPHOMA MODELS
E. Bernasconi, Bellinzona (Switzerland)

17:35 037 VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY FOR RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): PHASE 1 RESULTS
S. Heitner Enschede, Chicago, IL (USA)

17:45 038 TGR-1202, A NOVEL ONCE DAILY PI3K δ INHIBITOR, DEMONSTRATES CLINICAL ACTIVITY WITH A FAVORABLE SAFETY PROFILE, LACKING HEPATOTOXICITY IN PATIENTS WITH CLL AND B-CELL LYMPHOMA
O.A. Connor, New York, NY (USA)

17:55 039 ONGOING, FIRST-IN-HUMAN, PHASE 1 DOSE-ESCALATION STUDY OF INVESTIGATIONAL SYK INHIBITOR TAK-659 IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA
A.M. Petrich, Chicago, IL (USA)

18:05 040 ARGX-110, A NOVEL MONOCLONAL ANTIBODY TARGETING CD70, IS ASSOCIATED WITH BIOLOGICAL ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMAS
M. Maerevoet, Villejuif (France)

Aula Magna,
University
Campus

SHORT- AND LONG-TERM TOXICITY OF LYMPHOMA THERAPIES

Chair: M.F. Fey, Bern (Switzerland)

17:15 041 PULMONARY FUNCTION AND GRADE 3/4 CLINICAL EVENTS IN PET NEGATIVE PATIENTS TAKING PART IN THE INTERNATIONAL RATHL TRIAL (CRUK/07/033): A COMPARISON OF 12 VS 4 DOSES OF BLEOMYCIN
C. Hague, Manchester (UK)

17:25 042 SYK & PI3K δ PATHWAY INHIBITION RESULTED IN INCREASED RATES OF PNEUMONITIS: IMPLICATIONS FOR DEVELOPING FUTURE SMALL MOLECULE COMBINATIONS
P.M. Barr, Rochester, NY (USA)

17:35 043 CARDIOVASCULAR DISEASE AFTER THERAPY FOR HODGKIN LYMPHOMA: A DETAILED ANALYSIS OF 9 COLLABORATIVE EORTC-LYSA TRIALS
M. Maraldo, Copenhagen (Denmark)

17:45 044 A RADIATION DOSE-RESPONSE RELATIONSHIP FOR RISK OF CORONARY HEART DISEASE IN SURVIVORS OF HODGKIN LYMPHOMA: A CASE-CONTROL STUDY
B.M. Aleman, Amsterdam (The Netherlands)

17:55	045	ANTICOAGULANT/ANTIPLATELET THERAPY CONCOMITANT WITH IDELALISIB IN CHRONIC LYMPHOCYTIC LEUKEMIA AND INDOLENT NHL: USE AND OUTCOMES P. Ghia, Milan (Italy)
18:05	046	PATTERNS OF COGNITIVE DIFFICULTIES AFTER TREATMENT FOR LYMPHOMA O.C. Lindner, Manchester (UK)
19:00 – 21:00 2 parallel satellite symposia Room A		JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON CHALLENGING THE PARADIGMS IN B-CELL MALIGNANCIES Co-Chairs: M. Dreyling, Munich (Germany) and S. Rule, Plymouth (UK)
Room B		GILEAD SCIENCES EUROPE, LTD. NEW OPTIONS AND EVOLVING STRATEGIES IN THE MANAGEMENT OF HEMATOLOGICAL MALIGNANCIES Co-Chairs: M. Hallek, Cologne (Germany) and G. Salles, Lyon (France)

Thursday, June 18, 2015

08:30 – 18:30 Marquee		POSTER SESSION
08:00 – 08:45 5 parallel sessions Room A	Article number	MEET THE PROFESSOR SESSIONS 🎬
Room B	XII.	THERAPEUTIC EXPLOITATION OF AUTOLOGOUS T-CELL ACTIVATION IN B-CELL LYMPHOMA A. Younes, New York, NY (USA)
Room B	XI.	MANAGEMENT OF PEDIATRIC AND ADULT NON HODGKIN LYMPHOMA: WHAT LESSONS CAN EACH TEACH THE OTHER? B. Burkhardt, Muenster (Germany) and J.F. Seymour, Melbourne (Australia)
Cinema Corso	III.	CURRENT CONCEPTS IN PRIMARY CENTRAL NERVOUS LYMPHOMA G. Illerhaus, Stuttgart (Germany)
Auditorium, University Campus	IV.	MASSES IN THE MEDIASTINUM: PRIMARY MEDIASTINAL LYMPHOMA AND INTERMEDIATE TYPES P.M.W. Johnson, Southampton (UK)
Aula Magna, University Campus	V.	SMOLDERING MULTIPLE MYELOMA M.V. Mateos, Salamanca (Spain)
09:00 – 10:35 Room A and Marquee (overflow area)	Abstract number	SESSION 1 – LYMPHOMA BIOLOGY AND GENOMICS I Co-Chairs: R. Dalla-Favera, New York, NY (USA) and R.D. Gascoyne, Vancouver, BC (Canada)
09:00	047	GERMINAL CENTERS AND LYMPHOMAGENESIS R. Dalla-Favera, New York, NY (USA)
09:20	048	WHOLE EXOME SEQUENCING OF REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS IDENTIFIED RECURRENT MUTATIONS OF THE <i>EXPORTIN 1</i> GENE (<i>XPO1</i>) IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA SUBTYPE. A LYSA STUDY F. Jardin, Rouen (France)

09:35	049	RECURRENT SOMATIC MUTATIONS IN DIFFUSE LARGE B CELL LYMPHOMA ASSESSED BY HIGH-THROUGHPUT TARGETED SEQUENCING HIGHLIGHT MOLECULAR SUBTYPES' GENETIC DIVERGENCE: A LYSA STUDY S. Dubois, Rouen (France)
09:50	050	A MODIFIED AUTOANTIGEN IS THE FIRST MOLECULARLY DEFINED RISK FACTOR AND A DOMINANT ANTIGENIC TARGET / STIMULUS OF THE B-CELL RECEPTOR FROM ABC-TYPE DLBCL M. Pfreundschuh, Homburg (Germany)
10:05	051	THE ROLE OF TONIC BCR SIGNALING IN A MOUSE MODEL OF MYC-DRIVEN LYMPHOMA S. Casola, Milan (Italy)
10:20	052	RECURRENT MTORC1-ACTIVATING <i>RRAGC</i> MUTATIONS ARE A FEATURE OF FOLLICULAR LYMPHOMA J. Okosun, London (UK)
09:00 – 10:30 <i>5 parallel sessions</i>		“CASE DISCUSSION” SESSIONS Italian Lymphoma Foundation – FIL vs Cornell University and Memorial Sloan-Kettering Cancer Center in New York, NY (USA)
Room B		INDOLENT LYMPHOMA Chair: A. Davies, Southampton (UK) Discussants: L. Arcaini, Pavia (Italy) and J.P. Leonard, New York, NY (USA)
Room C		PEDIATRIC AND ADOLESCENT LYMPHOMA Chair: W. Wössmann, Giessen (Germany) Discussants: M. Pillon, Padua (Italy) and C.E. Allen, Houston, TX (USA)
Cinema Corso		CLL Chair: J.G. Gribben, London (UK) Discussants: D. Rossi, Novara (Italy) and A.D. Zelenetz, New York, NY (USA)
Auditorium, University Campus		T-CELL LYMPHOMA Chair: F. d'Amore, Aarhus (Denmark) Discussants: P. Corradini, Milan (Italy) and S. Horwitz, New York, NY (USA)
Aula Magna, University Campus		HODGKIN LYMPHOMA Chair: J.A. Radford, Manchester (UK) Discussants: P.L. Zinzani, Bologna (Italy) and A. Younes, New York, NY (USA)
10:35 – 11:00 Marquee		COFFEE BREAK
11:00 – 12:00 Room A, B and Marquee (overflow area)		SESSION 2 - ADVANCES IN CLL Co-Chairs: M. Hallek, Cologne (Germany) and A.D. Zelenetz, New York, NY (USA)
11:00	053	IN-VIVO STUDIES OF KINETICS IN CHRONIC LYMPHOCYTIC LEUKAEMIA PROVIDE DEFINITIVE EVIDENCE OF LYMPH-NODE RE-ENTRY AND SUGGEST THAT THERE IS A NON-PROLIFERATIVE SUB-CLONE K. Cuthill, London (UK)
11:15	054	THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI) – AN INTERNATIONAL META-ANALYSIS J. Bahlo, Cologne (Germany)

11:30	055	EFFICACY OF IBRUTINIB VS OFATUMUMAB BY CYTOGENETIC AND CLINICAL SUBGROUPS IN A PHASE 3 TRIAL IN PATIENTS WITH PREVIOUSLY TREATED CLL/SLL P. Thornton, Dublin (Ireland)
11:45	056	BFR (BENDAMUSTINE, FLUDARABINE, RITUXIMAB) ALLOGENEIC CONDITIONING IMPROVES SURVIVAL IN CLL I.F. Khouri, Houston, TX (USA)
12:00 – 13:00 Marquee		LUNCH TIME AND POSTER VIEWING <i>from 12:30 to 13:00 authors in front of their posters for discussion with attendees</i>
13:00 – 13:45 Room A, B and Marquee (overflow area)		HENRY RAPPAPORT MEMORIAL LECTURE 🏠 Chair: P. Gaulard, Créteil (France)
	002	MANTLE CELL LYMPHOMA, AN UNFOLDING STORY FROM THE MICROSCOPE TO THE GENOME E. Campo, Barcelona (Spain)
13:00 – 17:00 Cinema Corso		WORKSHOP FOR RADIATION ONCOLOGISTS Co-Chairs: M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark) Organized by International Lymphoma Radiation Oncology Group - ILROG <u>Part 1: TECHNICAL CHALLENGES IN RADIATION THERAPY OF LYMPHOMAS</u>
13:00		TECHNOLOGY IS THE PATH TO A SAFE RADIATION: TECHNIQUES AND DOSE CONSTRAINTS TO CUT DOWN THE LOSS FROM LATE SIDE EFFECTS B.S. Dabaja, Houston, TX (USA)
13:30		VOLUME DEFINITIONS, BREATH HOLD TECHNIQUES, AND MANAGEMENT OF UNCERTAINTIES IN THE COMBINED MODALITY SETTING L. Specht, Copenhagen (Denmark)
14:00		RADIOTHERAPY IN THE HEAVILY PRETREATED PATIENT: HOW TO MANAGE ADDED TOXICITY G. Mikhaeel, London (UK)
14:30		PROTONS OR PHOTONS? B.S. Dabaja, Houston, TX (USA)
15:15-15:30		COFFEE BREAK - inside Cinema Corso for workshop attendees
15:30-17:00		<u>Part 2: COMPETENCIES FOR RADIATION ONCOLOGISTS WITH SPECIAL EXPERTISE IN LYMPHOMAS</u> Panel discussion, led by M.K. Gospodarowicz, Toronto (Canada)
13:45 – 15:15 Room A, B and Marquee (overflow area)		SESSION 3 – MANTLE CELL LYMPHOMA Co-Chairs: M. Dreyling, Munich (Germany) and P. Martin, New York, NY (USA)
13:45	057	PI3K INACTIVATION AND REDOX STRESS MEDIATES THERAPEUTIC TARGETING OF CDK4 IN MCL S. Chen-Kiang, New York NY (USA)

14:00	058	PROGNOSTIC VALUE OF PROLIFERATION, CYTOLOGY, AND GROWTH PATTERN IN MANTLE CELL LYMPHOMA: RESULTS FROM RANDOMIZED TRIALS OF THE <i>EUROPEAN MCL NETWORK</i> E. Hoster, Munich (Germany)
14:15	059	RITUXIMAB, BENDAMUSTINE AND CYTARABINE (RBAC500) AS INDUCTION THERAPY IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: A PHASE 2 STUDY FROM THE FONDAZIONE ITALIANA LINFOMI C. Visco, Vicenza (Italy)
14:30	060	LENALIDOMIDE-RITUXIMAB-BENDAMUSTINE IN FIRST LINE FOR PATIENTS > 65 WITH MANTLE CELL LYMPHOMA: FINAL RESULTS OF THE NORDIC LYMPHOMA GROUP MCL4 (LENA-BERIT) PHASE I/II TRIAL A. Albertsson-Lindblad, Lund (Sweden)
14:45	061	RITUXIMAB MAINTENANCE VERSUS WW AFTER R-DHAP PLUS ASCT IN UNTREATED PATIENTS WITH MCL: INTERIM ANALYSIS OF THE LYMA TRIAL, A LYSA STUDY S. Le Gouill, Nantes (France)
15:00	062	RESULTS OF A RANDOMIZED PHASE II TRIAL OF R-HCVAD VS. R-BENDAMUSTINE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTS FOR PATIENTS WITH MANTLE CELL LYMPHOMA: US INTERGROUP S1106 R. Chen, Duarte, CA (USA)
14:45 – 16:55 Room C		SESSION 4 - PEDIATRIC LYMPHOMA Chair: W. Wössmann, Giessen (Germany)
14:45	063	NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA IN CHILDREN AND ADOLESCENTS: THERAPEUTIC APPROACHES AND GREY ZONE TO MATURE B-NHL C. Mauz-Körholz, Halle (Germany)
15:05	064	NEW TARGETS FOR THE TREATMENT OF MATURE B-NHL F. Jardin, Rouen (France)
15:25 – 15:40		COFFEE BREAK - inside Room C for session 4 attendees
15:40	065	RESULTS OF THE RANDOMIZED TRIAL EURO-LB02 ON LYMPHOBLASTIC LYMPHOMA IN CHILDREN AND ADOLESCENTS – A REPORT OF THE EUROPEAN INTERGROUP FOR CHILDHOOD NON-HODGKIN LYMPHOMA B. Burkhardt, Muenster (Germany)
15:55	066	RELAPSES IN CHILDREN/ADOLESCENTS WITH MATURE B-CELL LYMPHOMA/LEUKEMIA TREATED IN THE RITUXIMAB ERA - A STUDY OF THE SOCIÉTÉ FRANÇAISE DES CANCERS DE L'ENFANT V. Minard-Colin, Villejuif (France)
16:10	067	TREATMENT AND CHARACTERIZATION OF PATIENTS WITH BURKITT LYMPHOMA (BL): RESULTS FROM A SINGLE INSTITUTION IN NORTHERN UGANDA V. Calbi, Gulu (Uganda)
16:25	068	RISK-ADAPTED APPROACH FOR PATIENTS WITH RELAPSED OR REFRACTORY ALCL – FINAL REPORT OF THE PROSPECTIVE ALCL-RELAPSE TRIAL OF THE EICNHL S. Ruf, Giessen (Germany)
16:40	069	LYMPHOMA ASSOCIATED WITH A CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME: CLINICAL DESCRIPTION IN A FRENCH COHORT N. Lavoine, Villejuif (France)

15:15 – 15:35
Marquee

COFFEE BREAK

15:35 – 17:05
Room A and
Marquee
(overflow area)

SESSION 5 – T-CELL LYMPHOMA

Co-Chairs: K. Tobinai, Tokyo (Japan) and J.M. Vose, Omaha, NE (USA)

- 15:35 070 T-CELL PROJECT: AN INTERNATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS WITH AGGRESSIVE PERIPHERAL NK/T-CELL LYMPHOMA. LESSON FROM THE FIRST 1308 PATIENTS
M. Federico, Modena (Italy)
- 15:50 071 THE GENETIC LANDSCAPE OF HEPATOSPLENIC T-CELL LYMPHOMA REVEALS NOVEL STRATEGIES FOR TREATMENT AND RISK-STRATIFICATION
P. Gaulard, Créteil (France)
- 16:05 072 A PTCL, NOS SUBSET WITH MOLECULAR AND CLINICAL FEATURES SIMILAR TO AITL
M. Dobay, Lausanne (Switzerland)
- 16:20 073 RADIATION THERAPY FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (pcALCL): AN INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP (ILROG) MULTI-INSTITUTIONAL EXPERIENCE
R.T. Hoppe, Stanford, CA (USA)
- 16:35 074 TEN YEARS MEDIAN FOLLOW-UP OF THE NORDIC NLG-T-01 TRIAL ON CHOEP AND UPFRONT AUTOLOGOUS TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS
F. d'Amore, Aarhus (Denmark)
- 16:50 075 5-YEAR FOLLOW-UP OF THE SMILE PHASE II STUDY FOR NEWLY-DIAGNOSED STAGE IV, RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE
R. Suzuki, Izumo (Japan)

15:35 – 16:55
Room B

SESSION 6 – INTERFERING WITH BCR-NFKB PATHWAYS

Co-Chairs: M.A. Shipp, Boston, MA (USA) and F.E. Cotter, London (UK)

- 15:35 076 BCR SIGNALING AND SURVIVAL PATHWAYS IN LYMPHOMA
M.A Shipp, Boston, MA (USA)
- 15:55 077 IBRUTINIB IS HIGHLY ACTIVE AND PRODUCES DURABLE RESPONSES IN PREVIOUSLY TREATED WALDENSTRÖM'S MACROGLOBULINEMIA
S. Treon, Boston, MA (USA)
- 16:10 078 THE NOVEL DUAL PI3K/MTOR INHIBITOR PQR309 SHOWS PRECLINICAL ACTIVITY AS SINGLE AGENT OR IN COMBINATION AND TARGETS CENTRAL SIGNALING PATHWAYS IN B-CELL LYMPHOMAS
C. Tarantelli, Bellinzona (Switzerland)
- 16:25 079 PHASE 1 STUDY OF PI3K δ INHIBITOR INCB040093 ALONE OR IN COMBINATION WITH SELECTIVE JAK1 INHIBITOR INCB039110 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES
T.J. Phillips, Ann Arbor, MI (USA)
- 16:40 080 A FIRST-IN-HUMAN TRIAL OF CUDC-907, AN ORAL, FIRST-IN-CLASS, DUAL INHIBITOR OF PI3K AND HDAC, IN PATIENTS WITH REFRACTORY/RELAPSED LYMPHOMA AND MULTIPLE MYELOMA
A. Younes, New York, NY (USA)

17:15 – 18:15
6 parallel
sessions
Room A

“FOCUS ON...” SESSIONS

IMAGING

Chair: B.D. Cheson, Washington, D.C. (USA)

- 17:15 081 USE OF THE LUGANO CLASSIFICATION CRITERIA FOR PET/CT ASSESSMENT OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA AFTER IMMUNOCHEMOTHERAPY AND IRRADIATION IN THE IELSG-26 STUDY
L. Ceriani, Bellinzona (Switzerland)
- 17:25 082 PET SCORE FOLLOWING 3 CYCLES ABVD HAS GREATER PROGNOSTIC VALUE THAN PRE-TREATMENT RISK STRATIFICATION IN THE RAPID TRIAL IN EARLY STAGE HODGKIN LYMPHOMA (HL)
J.A. Radford, Manchester (UK)
- 17:35 083 BASELINE TOTAL METABOLIC VOLUME (TMTV0) PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) ENROLLED IN THE LNH07-3B LYSA TRIAL
O. Casasnovas, Créteil (France)
- 17:45 084 PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOUR VOLUME (TMTV0) MEASURED ON FDG-PET/CT IN PATIENTS WITH PERIPHERAL T CELL LYMPHOMA (PTCL)
A. Cottreau, Rouen (France)
- 17:55 085 LITTLE VALUE OF ROUTINE SURVEILLANCE IMAGING FOR PRIMARY CNS LYMPHOMAS IN FIRST REMISSION: RESULTS FROM A DANISH MULTICENTER STUDY
K. Juul Mylam, Odense (Denmark)
- 18:05 086 ROUTINE IMAGING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST REMISSION IS NOT ASSOCIATED WITH BETTER SURVIVAL: A DANISH-SWEDISH POPULATION-BASED STUDY
T.C. El-Galaly, Aalborg (Denmark)

Room B

TARGETTING CD30

Chair: P. Borchmann, Cologne (Germany)

- 17:15 087 BRENTUXIMAB VEDOTIN PLUS AVD FOR NON-BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA: A PHASE 2 TRIAL
J.S. Abramson, Boston, MA (USA)
- 17:25 088 PRELIMINARY EFFICACY AND SAFETY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY INVOLVED-SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA
C.H. Moskowitz, New York, NY (USA)
- 17:35 089 SEQUENTIAL BRENTUXIMAB VEDOTIN AND AVD FOR OLDER HODGKIN LYMPHOMA PATIENTS: INITIAL RESULTS FROM A PHASE 2 MULTICENTER STUDY
A.M. Evens, Boston, MA (USA)
- 17:45 090 A PHASE 1 STUDY OF BRENTUXIMAB VEDOTIN (BV) AND BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL) AND ANAPLASTIC LARGE T-CELL LYMPHOMA (ALCL)
J. Kuruvilla, Toronto, ON (Canada)
- 17:55 091 BRENTUXIMAB VEDOTIN DEMONSTRATES ANTITUMOR ACTIVITY IN CD30+ DLBCL
M.R. Smith, Boston, MA (USA)

18:05 092 UPDATED RESULTS OF A PHASE 2 TRIAL OF BRENTUXIMAB VEDOTIN COMBINED WITH RCHOP IN FRONTLINE TREATMENT OF PTS WITH HIGH-INTERMEDIATE/HIGH-RISK DLBCL
S.M. Ansell, Rochester, MN (USA)

Room C

EPIDEMIOLOGY AND INFECTIONS

Chair: L. Arcaini, Pavia (Italy)

17:15 093 INTERNATIONAL DLBCL STUDY FINDS BIOLOGICAL HETEROGENEITY BETWEEN ETHNICALLY DIVERSE COUNTRIES BUT SIMILAR IPI-ADJUSTED OUTCOMES
R. Carr, London (UK)

17:25 094 INVOLVEMENT OF MORAXELLA CATARRHALIS IN THE PATHOGENESIS OF HODGKIN LYMPHOMA (NODULAR LYMPHOCYTE PREDOMINANT TYPE, IGD-POSITIVE)
S. Hartmann, Frankfurt (Germany)

17:35 095 EPSTEIN-BARR VIRUS DNA LOAD IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF CLINICAL COURSE AND SURVIVAL
C. Visco, Vicenza (Italy)

17:45 096 EXPOSURE TO HEPATITIS B VIRUS (HBV), FAMILY HISTORY, AND B-CELL NON-HODGKIN LYMPHOMA (B-NHL): A CASE-CONTROL STUDY AMONG JEWS AND ARABS IN ISRAEL AND THE WEST BANK
O. Paltiel, Jerusalem (Israel)

17:55 097 EBV POSITIVE DLBCL OF THE ELDERLY IS A HETEROGENEOUS DISORDER WITH OUTCOME PREDICTED BY ITS IMMUNE MICROENVIRONMENT
C. Keane, Brisbane (Australia)

18:05 098 THE ROLE OF HBV-INFECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA
W. Xu, Nanjing (China)

Cinema Corso

MANAGEMENT OF T-CELL LYMPHOMA

Chair: F. d'Amore, Aarhus (Denmark)

17:15 099 CHOEP VS. CHOP GIVES BETTER RESULTS IN FIRST-LINE THERAPY OF T-CELL LYMPHOMA. A RETROSPECTIVE ANALYSIS FROM CZECH LYMPHOMA STUDY GROUP (CLSG) DATABASE
A. Janikova, Brno (Czech Republic)

17:25 100 LONG-TERM OUTCOME OF ADULTS WITH ALCL AFTER THE FIRST RELAPSE/PROGRESSION: A LYSA STUDY
D. Sibon, Paris (France)

17:35 101 PROSPECTIVE PHASE II TRIAL OF LENALIDOMIDE IN ASSOCIATION WITH CHOP IN ELDERLY PATIENTS WITH ANGIOIMMUNOBLASTIC T CELL LYMPHOMA (AITL): INTERIM ANALYSIS OF A LYSA STUDY
V. Safar, Lyon (France)

17:45 102 CLINICAL OUTCOMES AND PROGNOSTIC FACTORS OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA
H. Yhim, Jeonju (Republic of Korea)

17:55 103 P-GEMOX REGIMEN FOLLOWED BY EXTENSIVE INVOLVED-FIELD RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II ENKTL
H. Hui-Qiang, Guangzhou (China)

18:05 104 HDAC INHIBITOR COMBINATIONS EXHIBIT SYNERGY IN PRE- AND CLINICAL EXPERIENCES IN DRUG RESISTANT T-CELL LYMPHOMA
O.A. O'Connor, New York, NY (USA)

Auditorium,
University
Campus

NEW DRUG COMBINATIONS

Chair: J.P. Leonard, New York, NY (USA)

17:15 105 UBLITUXIMAB (TG-1101), A NOVEL GLYCOENGINEERED ANTI-CD20 MAB, IN COMBINATION WITH IBRUTINIB ACHIEVES 95% ORR IN PATIENTS WITH HIGH-RISK RELAPSED/REFRACTORY CLL
J. Burke, Aurora, CO (USA)

17:25 106 THE CHEMOTHERAPY-FREE TRIPLET OF UBLITUXIMAB, TGR-1202, AND IBRUTINIB IS SAFE AND HIGHLY ACTIVE IN RELAPSED B-CELL MALIGNANCIES
L. Nastoupil, Houston, TX (USA)

17:35 107 A PHASE 1 STUDY OF PI3K δ INHIBITOR INCB040093 ALONE OR IN COMBINATION WITH SELECTIVE JAK1 INHIBITOR INCB039110 IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA
A. Forero-Torres, Birmingham, AL (USA)

17:45 108 ABT-199 TRIGGERS APOPTOSIS, AND AUGMENTS IBRUTINIB CYTOTOXICITY IN CXCR4 WILD-TYPE AND WHITH MUTATED WALDENSTROEM MACROGLOBULINEMIA CELLS
J.J. Castillo, Boston, MA (USA)

17:55 109 VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 1B RESULTS
A.A. Chanan-Khan, Jacksonville, FL (USA)

18:05 110 CANCER ENERGY METABOLISM AS A THERAPEUTIC TARGET IN REFRACTORY MYC+ DIFFUSE LARGE B-CELL LYMPHOMA
C. Thieblemont, Paris (France)

Aula Magna,
University
Campus

ONGOING TRIALS

Chair: A. Davies, Southampton (UK)

17:15 OT01 THE IELSG-37 STUDY: A RANDOMIZED TRIAL ASSESSING THE ROLE OF MEDIASTINAL RADIOTHERAPY AFTER FRONT-LINE RITUXIMAB AND ANTHRACYCLINE CONTAINING REGIMENS IN PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)
M. Martelli, Rome (Italy)

17:25 OT02 ROCHOP STUDY: A PHASE III RANDOMIZED STUDY OF CHOP COMPARED TO ROMIDEPSIN-CHOP IN UNTREATED PERIPHERAL T-CELL LYMPHOMA
R. Delarue, Paris (France)

17:35 OT03 CLL2-BIG, -BAG, -BCG AND -BIO: FOUR PHASE-II TRIALS EVALUATING A SEQUENTIAL TAILORED AND TARGETED REGIMEN AIMING FOR TOTAL ERADICATION OF MRD IN AN ALL-COMER CLL POPULATION
P. Cramer, Cologne (Germany)

17:45 OT04 PHASE 2 STUDY OF VENETOCLAX (GDC-0199/ABT-199) PLUS BENDAMUSTINE AND RITUXIMAB (BR) VS. BR OR VENETOCLAX PLUS RITUXIMAB IN RELAPSED/REFRACTORY FL
W. Hiddemann, Munich (Germany)

17:55	OT05	DLC-002 (ROBUST): PHASE III RANDOMIZED, EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS R-CHOP VS R-CHOP IN PATIENTS WITH UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA A. Chiappella, Turin (Italy)
18:05	OT06	RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF IBRUTINIB/OBINUTUZUMAB VS. CHLORAMBUCIL/OBINUTUZUMAB FOR TREATMENT-NAÏVE CLL/SLL (PCYC-1130; ILLUMINATE) C. Moreno, Barcelona (Spain)
19:00 – 21:00 2 parallel satellite symposia Room A		CELGENE CORPORATION IMMUNE-BASED STRATEGIES TOWARDS ADVANCING THE TREATMENT OF B-CELL MALIGNANCIES Chair: F. Cavalli, Bellinzona (Switzerland)
Room B		MUNDIPHARMA ONCOLOGY CLL AND FOLLICULAR NHL: CRITICAL REVIEW OF THE CURRENT GUIDELINES AND FUTURE PERSPECTIVES Co-Chairs: J.G. Gribben, London (UK) and M. Ghilmini, Bellinzona (Switzerland)

Friday, June 19, 2015

08:30 – 18:30 Marquee		POSTER SESSION
08:00 – 08:45 5 parallel sessions	Article number	MEET THE PROFESSOR SESSIONS 🎤
Room A	I.	HODGKIN LYMPHOMA: SPECIAL CHALLENGES AND SOLUTIONS J. M. Connors, Vancouver, BC (Canada)
Room B	II.	CHALLENGES IN THE MANAGEMENT OF PTLD G. Gaidano, Novara (Italy)
Cinema Corso	IX.	IS IT ONLY ABOUT MYC? HOW TO APPROACH THE DIAGNOSIS OF DIFFUSE LARGE B-CELL LYMPHOMAS L. Quintanilla-Martinez, Tuebingen (Germany)
Auditorium, University Campus	VIII.	TREATMENT OF CLL, WHERE ARE WE HEADING? S.M. O'Brien, Irvine, CA (USA)
Aula Magna, University Campus	VI.	FDG-PET AS A BIOMARKER IN LYMPHOMA: FROM QUALITATIVE TO QUANTITATIVE ANALYSIS M. Meignan, Creteil (France)
09:00 – 10:35 Room A and Marquee (overflow area)	Abstract number	SESSION 7 - LYMPHOMA BIOLOGY AND GENOMICS II Co-Chairs: T.M. Mak, Toronto, ON (Canada) and L. Pasqualucci, New York, NY (USA)
09:00	111	ISOCITRATE DEHYDROGENASE (IDH) MUTATIONS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) T.M. Mak Toronto, ON (Canada)

09:20	112	RECURRENT MUTATIONS IN TCR (PATHWAY)-RELATED GENES IN TFH-DERIVED PERIPHERAL T-CELL LYMPHOMAS D. Vallois, Lausanne (Switzerland)
09:35	113	HBZ, BCL-XL, AKT, AND LOSS OF <i>INK4A/ARF</i> SYNERGISTICALLY TRANSFORM PRIMARY MURINE T CELLS AND ELICIT ATL-LIKE DISEASE IN MICE Y. Kasugai, Nagoya (Japan)
09:50	114	WHOLE GENOME SEQUENCING IN THE FRAMEWORK OF ICGC MMML-SEQ IDENTIFIES <i>PCBP1</i> AS RECURRENTLY MUTATED IN BURKITT LYMPHOMA S.M. Aukema, Kiel (Germany)
10:05	115	GENE, MIRNA AND PATHWAY SPECIFIC PROTEIN EXPRESSION ANALYSIS IN NEWLY DIAGNOSED MYC/BCL2 DOUBLE EXPRESSING DIFFUSE LARGE B-CELL LYMPHOMA E. Matsuki, New York, NY (USA)
10:20	116	MECHANISMS OF MALIGNANT TRANSFORMATION IN TP53 WILD-TYPE BURKITT LYMPHOMA IDENTIFIED BY INTEGRATION OF MOLECULAR AND FUNCTIONAL GENOMICS DATA J. Hüllein, Heidelberg (Germany)
09:00 – 10:30 5 parallel sessions		“CASE DISCUSSION” SESSIONS
Room B		AGGRESSIVE LYMPHOMA Chair: A. Lopez-Guillermo, Barcelona (Spain) Discussants: U. Vitolo, Turin (Italy) and P. Hamlin, New York, NY (USA)
Room C		LYMPHOMA RADIOTHERAPY Chair: L. Specht, Copenhagen (Denmark) Discussants: U. Ricardi, Turin (Italy) and J. Yahalom, New York, NY (USA)
Cinema Corso		MULTIPLE MYELOMA Chair: S.V. Rajkumar, Rochester, MN (USA) Discussants: M. Cavo, Bologna (Italy) and M. Coleman, New York, NY (USA)
Auditorium, University Campus		MANTLE CELL LYMPHOMA Chair: S. Le Gouill, Nantes (France) Discussants: M. Martelli, Rome (Italy) and P. Martin, New York, NY (USA)
Aula Magna, University Campus		CLINICO-PATHOLOGICAL DISCUSSION: BORDER-LINE CASES* Chair: M. Ghielmini, Bellinzona (Switzerland) Presenters: S. Dirnhofer, Basel (Switzerland), E. Campo, Barcelona (Spain) and S.H. Swerdlow, Pittsburgh, PA (USA) Discussants: M. Federico, Modena (Italy) and C.H. Moskowitz, New York, NY (USA) *supported by an unrestricted grant by sigma-tau Research Switzerland SA
10:30 – 10:50 Marquee		COFFEE BREAK
10:50 – 12:10 Room A, B and Marquee (overflow area)		SESSION 8 – HODGKIN LYMPHOMA Co-Chairs: R. Küppers, Essen (Germany) and J.A. Radford, Manchester (UK)
10:50	117	BIOLOGY OF HODGKIN LYMPHOMA R. Küppers, Essen (Germany)


11:10		EARLYFDG-PET ADAPTED TREATMENT IMPROVES THE OUTCOME OF EARLYFDG-PET-POSITIVE PATIENTS WITH STAGES I/II HODGKIN LYMPHOMA (HL): FINAL RESULTS OF THE RANDOMIZED INTERGROUP EORTC/LYSA/FIL H10 TRIAL J. Raemaekers, Nijmegen (The Netherlands)
11:25	118	INTERIM PET-ADAPTED CHEMOTHERAPY IN ADVANCED HODGKIN LYMPHOMA (HL). RESULTS OF THE SECOND INTERIM ANALYSIS OF THE ITALIAN GITIL/FIL DH0607 TRIAL A. Gallamini, Nice (France)
11:40	119	INTERIM PET RESPONSE-ADAPTED THERAPY IN ADVANCED STAGE HODGKIN'S LYMPHOMA: FINAL RESULTS OF THE PHASE II PART OF THE FONDAZIONE ITALIANA LINFOMI (FIL) HD0801 STUDY P.L. Zinzani, Bologna (Italy)
11:55	120	ANALYSIS OF PRIMARY-REFRACTORY HODGKIN LYMPHOMA PTS IN A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANT C.H. Moskowitz, New York, NY (USA)
12:10 – 13:00 Room E		13-ICML PRESS CONFERENCE open to all journalists
12:10 – 13:00		LUNCH TIME AND POSTER VIEWING , Marquee Parco Ciani <i>from 12:30 to 13:00 authors in front of their posters for discussion with attendees</i>
13:00 – 13:50 Room A, B and Marquee (overflow area)		JOHN ULTMANN MEMORIAL LECTURE* 🎤 Chair: E.S. Jaffe, Bethesda, MD (USA) *sponsored by European School of Oncology - ESO
	003	THIRTY YEARS OF PROGRESS IN CUTANEOUS LYMPHOMA RESEARCH R. Willemze, Leiden (The Netherlands)
13:50 – 15:20 Room A, B and Marquee		SESSION 9 – INDOLENT LYMPHOMA Co-Chairs: B.S. Kahl, Madison, WI (USA) and A. Lopez-Guillermo, Barcelona (Spain)
13:50		13-ICML WORKSHOP REPORT R.D. Gascoyne, Vancouver, BC (Canada)
14:05	121	RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA AND OUTCOME IN THE IMMUNOCHEMOTHERAPY ERA: ANCILLARY STUDY FROM THE PRIMA TRIAL C. Sarkozy, Pierre Bénite (France)
14:20	122	COMPLETE RESPONSE RATE AT 30 MONTHS (CR30) AS A SURROGATE ENDPOINT IN FIRST-LINE FOLLICULAR LYMPHOMA: A PROSPECTIVELY SPECIFIED ANALYSIS USING INDIVIDUAL PATIENT DATA D.J. Sargent, Rochester, MN (USA)
14:35	123	GADOLIN: PRIMARY RESULTS OF A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT LYMPHOMA B.D. Cheson, Washington, D.C. (USA)
14:50	124	A SIMPLE AND EFFECTIVE MALT LYMPHOMA-SPECIFIC PROGNOSTIC INDEX GENERATED FROM THE DATASET OF THE IELSG-19 CONTROLLED CLINICAL TRIAL C. Thieblemont, Paris (France)

15:05	125	BING-NEEL SYNDROME: A MULTI-INSTITUTIONAL RETROSPECTIVE STUDY J.J. Castillo, Boston, MA (USA)
15:20 – 15:40		BREAK
15:40 – 16:15 Room A, B and Marquee (overflow area)		CONTROVERSY EARLY-STAGE HL: SHOULD INTERIM PET-BASED THERAPY BE CONSIDERED ROUTINE CLINICAL PRACTICE? Chair: T.A. Lister, London (UK)
	006 007	NO: M. Hutchings, Copenhagen (Denmark) vs YES: J.M. Connors, Vancouver, BC (Canada)
16:15 – 17:45 Room A, B and Marquee (overflow area)		SESSION 10 – AGGRESSIVE LYMPHOMA Co-Chairs: U. Vitolo, Turin (Italy) and L.H. Sehn, Vancouver, BC (Canada)
16:15	126	GRAY ZONE LYMPHOMA (GZL): CHARACTERISTICS, OUTCOMES AND PROGNOSTICATION AMONG A LARGE MULTICENTER COHORT A.M. Evens, Boston, MA (USA)
16:30	127	RATIOS OF T-CELLS TO TUMOUR ASSOCIATED MACROPHAGES AND PD-1 AXIS MOLECULES, ADD TO THE PREDICTIVE POWER OF CONVENTIONAL PROGNOSTICATORS IN DIFFUSE LARGE B CELL LYMPHOMA M. Gandhi, Brisbane (Australia)
16:45	128	CONTINUED RISK OF RELAPSE INDEPENDENT OF TREATMENT MODALITY IN LIMITED STAGE DIFFUSE LARGE B-CELL LYMPHOMA: FINAL AND LONG-TERM ANALYSIS OF SWOG STUDY S8736 D.M. Stephens, Salt Lake City, UT (USA)
17:00	129	TREATMENT SELECTION AND SURVIVAL OUTCOMES IN EARLY-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: DOES MODERN CHEMOTHERAPY REPLACE THE NEED FOR RADIOTHERAPY? J.A. Vargo, Pittsburg, PA (USA)
17:15	130	FRONT LINE THERAPY WITH R-CODOX-M & R-IVAC IN POOR RISK DIFFUSE LARGE B CELL LYMPHOMA (IPI 3-5) YIELDS A GOOD OUTCOME WITHOUT TRANSPLANTATION: A PHASE 2 UK NCRI/LLR TRIAL A.K. McMillan, Nottingham (UK)
17:30	131	VALIDATION OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL) PROGNOSTIC MODEL FOR CNS RELAPSE IN A LARGE COHORT OF PET/CT STAGED PATIENTS T.C. El-Galaly, Aalborg (Denmark)
17:45 Marquee		FAREWELL APERO
18:45 – 19:45 Room A		ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND - IOSI <i>Supported by an unrestricted educational grant by GILEAD SCIENCES EUROPE, LTD.</i> THE BIG DEBATE: SHOULD WE ALWAYS AIM AT MINIMAL RESIDUAL DISEASE ERADICATION? Chair: M. Ghielmini, Bellinzona (Switzerland)

Saturday, June 20, 2015

- 08:00 – 10:30
Room 159,
University
Campus
- SPECIAL SESSION - CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING***
A. Kiil Berthelsen, Copenhagen (Denmark), S. Qi, New York, NY (USA) and Beijing (China), L. Specht, Copenhagen (Denmark)
Organized by International Lymphoma Radiation Oncology Group - ILROG and European Society for Radiotherapy and Oncology – ESTRO
* **compulsory pre-registration**
- 08:30 – 10:00
2 parallel sessions
Room A
- SESSION 11 – PRIMARY CNS LYMPHOMA**
Co-Chairs: G. Illerhaus, Stuttgart (Germany) and A.J. Ferreri, Milan (Italy)
- 08:30 132 HIGH FREQUENCY OF *MYD88* MUTATIONS IN VITREORETINAL B-CELL LYMPHOMA: A VALUABLE TOOL TO IMPROVE DIAGNOSTIC YIELD OF VITREOUS BODY ASPIRATES
I. Bonzheim, Tuebingen (Germany)
- 08:45 133 GENETIC BASIS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
K. Yoshida, Kyoto (Japan)
- 09:00 134 RITUXIMAB, METHOTREXATE, PROCARBAZINE AND LOMUSTINE FOR ELDERLY PRIMARY CNS LYMPHOMA PATIENTS – THE PRIMAIN-STUDY BY THE GERMAN COOPERATIVE PCNSL GROUP
B. Kasenda, Stuttgart (Germany)
- 09:15 135 MANAGEMENT AND OUTCOME OF PRIMARY CNS LYMPHOMA AT FIRST RELAPSE/PROGRESSION: ANALYSIS OF 256 PATIENTS FROM THE FRENCH LOC NETWORK
S. Langner-Lemercier, Rennes (France)
- 09:30 136 PHASE I/II STUDY OF TEDDI-R WITH IBRUTINIB IN UNTREATED AND RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA
K. Dunleavy, Bethesda, MD (USA)
- 09:45 137 LENALIDOMIDE IS HIGHLY ACTIVE IN RECURRENT CNS LYMPHOMAS: PHASE I INVESTIGATION OF LENALIDOMIDE PLUS RITUXIMAB AND OUTCOMES OF LENALIDOMIDE AS MAINTENANCE MONOTHERAPY
J.L. Rubenstein, San Francisco, CA (USA)
- 08:40 – 10:00
Room B
- SESSION 12 – IMMUNOTHERAPY**
Co-Chairs: R. Levy, Stanford, CA (USA) and F. Morschhauser, Lille (France)
- 08:40 138 IMMUNOTHERAPY OF LYMPHOMA 2015
R. Levy, Stanford, CA (USA)
- 09:00 139 PHASE II TRIAL OF CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELLS DIRECTED AGAINST CD19 IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL, FOLLICULAR, AND MANTLE CELL LYMPHOMAS
S.J. Schuster, Philadelphia, PA (USA)
- 09:15 140 A PHASE IIA STUDY OF SINGLE-AGENT MOR208, AN FC-OPTIMIZED ANTI-CD19 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
P.L. Zinzani, Bologna (Italy)

09:30	141	PHASE I, FIRST-IN-HUMAN TRIAL OF BI 836826 (AN ANTI-CD37 ANTIBODY) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) S. Stilgenbauer, Ulm (Germany)
09:45	142	TWO DOSES OF POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): DURABLE RESPONSES AT LOWER DOSE F. Morschhauser, Lille (France)
10:00 – 11:20 Room A and B		SESSION 13 – TARGETTING INTRACELLULAR PATHWAYS Co-Chairs: M. Seto, Nagoya (Japan) and J.F. Seymour, Melbourne (Australia)
10:00	143	Introduction: GENETIC AND EPIGENETIC HETEROGENEITY OF MALIGNANT LYMPHOMA: CHALLENGING FEATURES M. Seto, Nagoya (Japan)
10:20	144	EPIGENETIC CONTROL OF CELLULAR SENESCENCE IN TUMOR DEVELOPMENT AND LYMPHOMA TREATMENT C.A. Schmitt, Berlin (Germany)
10:35	145	PHASE 1 STUDY OF E7438 (EPZ-6438), AN ENHANCER OF ZESTE-HOMOLOG 2 (EZH2) INHIBITOR: DOSE DETERMINATION AND PRELIMINARY ACTIVITY IN NON-HODGKIN LYMPHOMA V. Ribrag, Villejuif (France)
10:50	146	SELINEXOR SHOWS ACTIVITY IN DOUBLE-HIT DIFFUSE LARGE B-CELL LYMPHOMA IN PRE-CLINICAL MODELS & IN PATIENTS WITH RELAPSED/REFRACTORY DOUBLE-HIT DLBCL R. Garzon, Columbus, OH (USA)
11:05	147	PHASE 1 PRELIMINARY SAFETY, EFFICACY AND BIOMARKER DATA FROM VENETOCLAX (ABT-199/GDC-0199) + BENDAMUSTINE AND RITUXIMAB IN R/R NON-HODGKIN'S LYMPHOMA S. de Vos, Los Angeles, CA (USA)
11:20 – 11:45 Room A and B		13-ICML HIGHLIGHTS  “TAKE HOME MESSAGES” J.W. Friedberg, Rochester, NY (USA)
11:45 – 11:55		CLOSURE AND FAREWELL F. Cavalli, Bellinzona (Switzerland)
13:30 – 18:00 Room B I		WORKSHOP: “CANINE LYMPHOMA: STATE OF THE ART AND COMPARATIVE ASPECTS WITH HUMAN DISEASE”* Co-Chairs: S. Comazzi, Milan (Italy), F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy) Organized by the European Canine Lymphoma Group *open to all 13-ICML attendees

 This icon denotes presentations that will be available online, only for 13-ICML attendees, between July 15 and September 15, 2015.